Dr. Khong on the Benefit of Neoadjuvant Endocrine Therapy in ER+ Breast Cancers

Video

In Partnership With:

Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.

Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.

Neoadjuvant therapy is usually used to downstage tumors so that surgery can be optimally performed. In patients who require a mastectomy, downstaging the tumor can enable a lumpectomy. This can conserve the breast rather than removing the whole breast with a mastectomy. The use of neoadjuvant endocrine therapy can also convert patients with an unresectable tumor to a resectable tumor.

In addition, it can confer longtime survival benefit, says Khong. The side effects are very minimal compared with those seen in chemotherapy. The benefit is very similar to, and in some cases better than, chemotherapy. It’s important to note that the benefit of neoadjuvant endocrine therapy is not inferior to chemotherapy, says Khong.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD